Table 1.

Vertebral fracture data reported in head-to-head studies.

Trial name: first author and year (Ref.)	Treatments, n analysed	Follow-up (months)	Vertebral fracture outcomes n (%) (reported between-group difference)
Panico et al., 2011 postmenopausal women with severe osteoporosis	ALN, 39 TPTD, 42	18	ALN 6/39 (15.7) TPTD 1/42 (2.4) RR 0.15, 95% CI 0.02–1.23 NS
Hadji et al., 2012 postmenopausal women with osteoporosis	RIS, 350 TPTD, 360	6	RIS, 18/350 (5.1) TPTD, 15/360 (4.2), RR 0.83, 95% CI 0.41–1.58 NS
Miller et al., 2016a postmenopausal women with osteoporosis	ABL 824 TPTD 818	18	ABL 4/824 TPTD 6/818 RR 0.66, 95% CI 0.18–2.40, NS
ARCH: Saag et al., 2017 postmenopausal women with osteoporosis	ALN, 2047 ROMO, 2046	12	ALN, 128/2047 (6.3) ROMO, 82/2046 (4.0) RR 0.63, 95% CI 0.47 to 0.85 p = 0.003
VERO: Kendler et al., 2017 postmenopausal women with osteoporosis	RIS, 533 TPTD, 516	24	RIS, 64/533 (12.0) TPTD, 28/516 (5.0) RR 0.44, 95% CI 0.29–0.68; p < 0.0001

ALN – Alendronate, DEN – Denosumab, ROMO – Romosozumab, RIS – Risedronate, TPTD – Teriparatide, ZOL – Zoledronate, ABL-Abaloparatide, NS- not significant.